# Nuo Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [Nuo Therapeutics, Inc.](/companies/aurx.md) (CIK 1091596)
- Form: 10-Q
- Filed: 2018-11-16
- Accepted by EDGAR: Nov 16, 2018, 17:10 ET
- Period: 2018-09-30
- Accession: 0001437749-18-021015
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1091596/000143774918021015/aurx20180930_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1091596/000143774918021015/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $260.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $558.5k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $44.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $132.1k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | $215.4k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $426.4k | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $95.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $493.6k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$411.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | −$649.9k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | −$1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 23,722,400 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 23,128,993 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2018-09-30 | $250.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $613.8k | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $759.8k | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $1.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2018-09-30 | −$581.8k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 44,244 characters.

*The following discussion and analysis of the financial condition and results of operations of Nuo Therapeutics, Inc. ("Nuo Therapeutics," the "Company," "we," "us," or "our") should be read in conjunction with the financial statements and related notes appearing elsewhere in this Quarterly Report and our Annual Report on Form 10-K for the year ended December 31, 2017 (the “Annual Report”), filed with the U.S. Securities and Exchange Commission, or the Commission on April 16, 2018.*

### Special Note Regarding Forward Looking Statements

Some of the information in this Quarterly Report (including this section) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance, or achievements, and may contain the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “the facts suggest,” “will,” “will be,” “will continue,” “will likely result,” “could,” “may” and words of similar import. These statements reflect the Company’s current view of future events and are subject to certain risks and uncertainties as noted in this Quarterly Report and in other reports filed by us with the Securities and Exchange Commission, including Forms 8-K, 10-Q, and 10-K. These risks and uncertainties include, among others, the following:

- significant uncertainty surrounding continuation of the Coverage with Evidence Development, or CED, program due to an absence of resources sufficient to conduct the current CED program in any realistic time frame;
- significant uncertainty surrounding an agreed path forward for Aurix as an accessible product option for physicians treating Medicare beneficiaries with chronic wounds – in the absence of such a path, the Company will likely have to cease operations;
- the possibility that a more comprehensive and definitive analysis of the wound healing data described under "*Recent Developments - Status of CED Studies"* could come to materially different conclusions than the results of our limited and preliminary analysis described therein
- the continuing rapid depletion of our cash resources, our need for immediate and substantial additional financing (without which we face liquidation) and our ability to obtain that financing, including in light of our outstanding convertible notes, Series A preferred stock and the low share price and significant volatility with respect to our common stock - if we were required to liquidate today, the holders of our common stock would not receive any consideration for their common stock;
- the fact that we have no significant assets left to monetize other than the Aurix System itself;
- our limited sources of working capital;
- whether the Centers for Medicare & Medicaid Services, or CMS, will increase the standard national payment rate for physicians for the use of Aurix so that it will provide an adequate payment to physicians to increase such use sufficiently;
- our history of losses and expectation that, even if we were to obtain sufficient financing immediately to continue operating, we will incur losses in the foreseeable future;
- our limited operating experience;
- acceptance of our products by the medical community and patients, especially in light of uncertainties surrounding CED programs in general;
- our ability to obtain adequate reimbursement from third-party payors;
- whether the advisory opinion issued in response to a petition to the Office of Inspector General, or OIG, of the Department of Health and Human Services, or DHHS, effectively permitting the petitioning hospital to reduce or waive Medicare patients’ 20% co-payment with respect to the Aurix CED program in certain cases, will in fact cause other healthcare providers to make similar waivers;
- whether CMS will continue to consider their treatment of the geometric mean cost of the services underlying the Aurix System, or Aurix, to be comparable to the geometric mean cost of Ambulatory Payment Classification ("APC 5054") in the future;
- our ability to maintain classification of Aurix as APC 5054;
- whether CMS will continue to maintain the current national average reimbursement rate of $1,568 per Aurix treatment, and, more generally, our ability to be reimbursed at a profitable national average rate per application in the future;
- uncertainties surrounding the price at which our common stock will continue trading on the OTC market (with such price having declined substantially) and the limited trading volume or liquidity of our common stock - as a result of our decrease in net tangible assets below the required threshold for trading on OTCQX, our common stock moved to the OTCQB market effective June 7, 2018, which could further restrict liquidity and our ability to raise capital through equity issuances;
- our reliance on several single source suppliers and our ability to source raw materials at affordable costs;
- our ability to protect our intellectual property;
- our compliance with governmental regulations;
- the success of our clinical study protocols under our CED program;
- our ability to contract with healthcare providers;
- our ability to successfully sell and market the Aurix System (as defined below);
- our ability to attract and retain key personnel; and
- our ability to successfully pursue strategic collaborations to help develop, support or commercialize our products.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements.

In addition to the risks identified under the heading “Risk Factors” in our Annual Report and the other filings referenced above, other sections of this report may include additional factors which could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on our business, or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

The Company undertakes no obligation and does not intend to update, revise or otherwise publicly release any revisions to its forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events.

### Business Overview

We are a regenerative therapies company developing and marketing the Aurix product for chronic wound care primarily within the U.S. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous (from self) biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long-term recovery in inherently complex chronic conditions with significant unmet medical needs.

Our current commercial offering consists of a point of care technology for the safe and efficient separation of autologous (i.e., the patient’s own) blood to produce a platelet based therapy for the chronic wound care market (“Aurix” or the “Aurix System”). The U.S. Food and Drug Administration, or FDA, cleared the Aurix System for marketing in 2007 as a device under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or FDCA. Aurix is the only platelet derived product cleared by the FDA for chronic wound care use and is indicated for most exuding wounds. The advanced wound care market, within which Aurix competes, is composed of advanced wound care dressings, wound care devices, and wound care biologics.

A 2012 Medicare National Coverage Determination, or NCD, from the Centers for Medicare & Medicaid Services, or CMS, reversed a twenty year old non-coverage decision for autologous blood derived products used in wound care; this NCD allows for Medicare coverage under the Coverage with Evidence Development, or CED, program.

We have been conducting clinical studies for Aurix under this CED program. Under the CED program, CMS provides reimbursement for items or services on the condition that they be furnished in approved clinical protocols or in the collection of additional clinical data. Current sales outside of the Federal Supply Schedule and Medicare reimbursement are practically limited to patients participating in certain Company-sponsored clinical studies approved by CMS under the CED program.

### Recent Developments

### Status of CED program

On October 22, 2018, Company’s management met with representatives of CMS’ Coverage and Analysis Group (CAG) to discuss the status of the three study protocols (for diabetic foot ulcers, venous leg ulcers and pressure ulcers) totaling 2,200 patients under the Company’s CED program. The Company presented to CAG its view that completion of the studies to full enrollment was no longer considered practical and that completion of the CED studies as presently structured was untenable. The Company discussed with CAG a variety of difficulties and limitations that have arisen during the conduct of the CED program that have contributed to slow enrollment, closure of study sites, and concerns about overall data integrity.

While the Company views completion of the CED protocols as presently designed as not feasible, it has conducted a preliminary and limited internal analysis of wound healing data using the currently available patients and datasets. Of the 297 patient randomizations as of October 15, 2018, 269 patients (9 remain on study and 19 were either never treated or without any data) across the three study protocols were considered suitable for analysis in essentially a modified intent to treat population. The results of this limited preliminary internal analysis were as follows:

- Diabetic foot ulcers constituted the largest share of the evaluable patients with 121. Complete healing, as defined in the protocol, was found to be statistically significant in the Aurix arm versus the usual and customary care control arm.
- Neither the venous leg ulcer nor pressure ulcer protocols were found to have any statistically significant differences in complete wound healing.

Other protocol endpoints (e.g., wound healing trajectories, validated quality of life measures) have not yet been analyzed in any substantive manner. The Company expressed to CAG its intention to pursue publication of the relevant data in a peer-reviewed scientific journal should CMS reopen the national coverage determination (NCD) for Aurix. The Company cautions that its analysis to date was limited and preliminary, and subject to independent review and analysis of the related datasets. A more comprehensive and definitive analysis could come to materially different conclusions.

However, on the basis of the limited and preliminary internal analysis, the Company expressed to CAG its view that the data on diabetic foot ulcers, when viewed in conjunction with analyses in prior publications, support a conclusion that Aurix is reasonable and necessary for Medicare beneficiaries, and that the Company was therefore prepared to initiate a formal request to reopen the NCD.

The Company also discussed with CAG the general conditions it believed would be necessary to adjust the data collection efforts for venous leg and pressure ulcers to allow a robust set of evaluable data to be collected in a reasonable time frame. The Company reiterated its view that Aurix can be an effective wound management product option for clinicians treating these difficult etiologies. During the meeting the Company was joined by the principal investigator at the CED study site responsible for slightly in excess of 25% of total study enrollment. He communicated to CAG that pressure ulcers have essentially no viable treatment options and that Aurix is a notably effective product in treating these wounds.

The Company communicated to CAG that, in the absence of an agreed path forward for Aurix as an accessible product option for physicians treating Medicare beneficiaries with chronic wounds, the Company will likely proceed to cease operations and the CED effort would be officially terminated due to an absence of resources sufficient to conduct and conclude the current CED program in any realistic time frame. The Company can provide no assurance that CMS will respond in a manner that the Company views as practical and executable given overall constraints on available resources or in a timeframe necessary for the Company to avoid a cessation of business operations.

### Sale of Intellectual Property and License and Service Agreement with Rohto

We refer to Note 3 – *Distribution, Licensing and Collaboration Arrangements* for a description of our amended license and distribution agreement (“Amended License and Distribution Agreement”) with Rohto Pharmaceutical Co., Ltd. (“Rohto”), which description is incorporated herein by reference.

On October 24, 2018, the Company entered into an Agreement for Sale of Intellectual Property (the “IP Sale Agreement”) and a License and Service Agreement (the “Service Agreement” and collectively the “Agreements”) with Rohto.

The IP Sale Agreement provides for the sale to Rohto of the intellectual property under license pursuant to the Amended License and Distribution Agreement (consisting of two Nuo patents in Japan, Nuo know-how in Japan and trademarks for Aurix and AutoloGel in Japan). The IP Sale Agreement provides that, upon the completion of such transfers and payments, the Amended License and Distribution Agreement will be terminated. Under the IP Sale Agreement, we are subject to a five-year non-compete in Japan.

Under the Service Agreement, we agreed to the sale of a patent application in Brazil, the grant of a royalty free license to our know how in the Field of Use in Brazil and India, and the grant of a royalty-free non-exclusive license to the use of our device patent in the Field of Use in the United States, Canada and Mexico. The latter license becomes effective if and only if we cease our business with respect to the Aurix System or grant a non-exclusive license to a third party to use the device patent in the Field of Use in the United States, Canada and Mexico. The “Field of Use” is defined as the use of the Aurix System and the modified medical device being developed by Rohto under the Japan patents sold to Rohto for all wound care and topical dermatology applications in human and animal medicine. Under the Service Agreement, we are subject to a non-compete in Brazil and India.

The aggregate consideration receivable under the Agreements is $750,000, with $500,000 received on November 8, 2018 and the balance due within 15 days of the delivery by us of the executed documents necessary to effect the transfer of the relevant intellectual property rights to Rohto.

### Aldeflour Royalty Buyout

On September 28, 2018, Aldagen, Inc. (“Aldagen”), a wholly owned subsidiary of the Company, entered into a first amendment (the “Amendment”) to the existing license agreement (the “License Agreement”) with STEMCELL Technologies Canada, Inc. (previously known as STEMCELL Technologies, Inc.) (“STEMCELL”) to provide for the buyout by STEMCELL of the remaining royalty obligations under the License Agreement in exchange for a payment of $195,000. Upon receipt of the payments of $100,000 on October 31, 2018 and $95,000 by December 15, 2018, STEMCELL will have a fully paid up, irrevocable and royalty free license to the intellectual property under the License Agreement for the Aldeflour product currently sold by STEMCELL. Aldagen additionally agreed to the transfer of the Aldeflour trademark to STEMCELL upon receipt of the final payment described above.

### Issuance of Convertible Notes and Warrants

On September 17, 2018, the Company entered into securities purchase agreements with Auctus Fund, LLC (“Auctus”) and EMA Financial, LLC (“EMA” and, collectively with Auctus, the “Investors”) for the issuance and sale to the Investors of 12% convertible promissory notes, each in the principal amount of $175,000, for an aggregate purchase price of $315,800 (reflecting a combined $34,200 in original issue discount and transaction fees). On September 17, 2018, the Company issued the notes to the Investors. Pursuant to the purchase agreements, the Company also issued to each Investor a warrant exercisable to purchase 233,333 shares of the Company’s common stock, for an aggregate of 466,666 shares of common stock, subject to adjustment as referenced below.

The purchase agreements contain certain representations, warranties and covenants by, among and for the benefit of the respective parties. The purchase agreements also provide for customary indemnification of the Investors by the Company.

The notes mature nine months from the date of issuance (June 17, 2019) and, in addition to any original issue discount, accrue interest at a rate of 12% per year. The Company may prepay the notes, in whole or in part, for 130% of outstanding principal and interest ending on the date that is 90 days following the date of issuance, and for 145% of outstanding principal and interest at any time commencing on the date that is 91 days following the date of issuance and ending on the date that is 180 days following the date of issuance, but only if the Company is not then in default under the notes. Beginning on the date that is 181 days following the date of issuance, the Company may no longer prepay the notes. The maturity date of the note issued to EMA may be extended up to one year beyond the original maturity date at the option of EMA.

After six months from the date of issuance, the Investors may convert the notes, at any time, in whole or in part, into shares of the Company’s common stock, at a conversion price corresponding to a 40% discount to the average of the two lowest trading prices of the common stock during the 25 trading days prior to the conversion, subject to certain adjustments and price-protection provisions contained in the notes, including full-ratchet anti-dilution protection in the case of dilutive issuances of securities that do not meet the requirements of “exempt issuances” as defined in the notes. The Company is required to maintain authorized and unissued shares of its common stock equal to seven times the number issuable upon conversion of the notes. Each note contains potential additional discounts to the conversion price upon the occurrence of an event of default or specified other events related to the trading status of the Company’s common stock (which would result in a higher number of shares issued upon conversion).

The notes include certain event of default provisions, a default interest rate of 24% per year and certain penalties for specified breaches that would be added to the principal amount of the relevant note. Upon the occurrence of an event of default, an Investors may require the Company to redeem their note (or convert it into shares of common stock) at 150% of the outstanding principal balance plus accrued and unpaid interest. The notes also restrict the Company’s ability to make distributions to its shareholders, repurchase its shares, borrow funds, or sell its assets (with limited exceptions).

The warrants are exercisable at any time, at an exercise price per share equal to $0.15, subject to certain adjustments and price protection provisions (including full ratchet anti-dilution protection) contained in the warrants. The warrants have five-year terms.

The transaction documents also include most favored nations provisions and limitations on the Company’s ability to offer additional securities (unless the use of proceeds is to repay the notes).

### Results of Operations

### Comparison of Three Months Ended September 30, 2018 and 2017

The amounts presented in this comparison section are rounded to the nearest thousand.

### Revenue and Gross Profit

The following table presents the profitability of sales for the periods presented:

|  | Three months ended September 30, 2018 | Three months ended September 30, 2017 |
| --- | ---: | ---: |
| Product sales | $65,000 | $122,000 |
| Royalties | 195,000 | 40,000 |
| Total revenues | 260,000 | 162,000 |
| Product cost of sales | 45,000 | 264,000 |
| Total cost of sales | 45,000 | 264,000 |
| Gross profit (loss) | $215,000 | $(102,000) |
| Gross margin % | 83% | (63)% |

19

Revenues increased by $98,000 to $260,000 comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The increase was primarily attributable to a $155,000 increase in royalty revenue for the three months ended September 30, 2018 in connection with the Aldeflour royalty buyout described above under “*Recent Developments – Aldeflour Royalty Buyout.”* As a result of the Aldeflour royalty buyout, the Company will no longer be receiving related royalties. The effect of the royalty buyout accrual was partially offset by a $57,000 decrease in Aurix product sales. Aurix revenues declined primarily due to lower enrollment in the CED study protocols (and resulting fewer treatments) as the Company's limited resources impacted viability perceptions. Management believes quarterly Aurix revenues will remain insufficient to cover operating expenses until such time as CED enrollment can be substantially increased and/or alternative non-CED Aurix revenues can be established. Please refer to “*Recent Developments – Status of CED Program” above.*

Overall gross profit increased $317,000 to $215,000 while overall gross margin increased to 83% from (63)%, comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The increase in gross profit primarily reflects (i) approximately $155,000 of increased royalty revenue (with no associated cost) in the quarter ended September 30, 2018 due to the Aldeflour royalty buyout described above; and (ii) the effect of non-cash amortization expense recorded in the quarter ended September 30, 2017 relating to (x) approximately $183,000 of intangible technology assets and (y) approximately $30,000 for a prepaid royalty. As all intangible assets were considered impaired as of December 31, 2017, no amortization expense was recognized in the three months ended September 30, 2018.

### Operating Expenses

Total operating expenses decreased approximately $646,000 to approximately $627,000 comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The decrease was primarily due to decreases across substantially all expense components from reduced headcount and numerous cost saving initiatives. A discussion of the various components of operating expenses follows below.

S*ales and Marketing*

Sales and marketing expenses decreased approximately $146,000 (90%) to approximately $17,000 comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The decrease was primarily due to elimination of the remaining direct sales personnel early in the first quarter 2018.

#### Research and Development

Research and development expenses decreased approximately $204,000 (68%) to approximately $95,000 comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The decrease was primarily due to (i) reduced headcount in the clinical affairs area and corresponding lower compensation expenses, (ii) no depreciation expense in the three months ended September 30, 2018 as software costs are now fully depreciated, and (iii) decreased clinical affairs costs for reduced CED activity.

#### General and Administrative

General and administrative expenses decreased approximately $296,000 (36%) to $515,000 comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The decrease was primarily due to (i) lower compensation expense due to reduced headcount, and (ii) lower professional fees including legal expenses and (iii) decreased depreciation expenses which were partially offset by a bad debt recovery in the three months ended September 30, 2017.

#### Other Income (Expense)

Other expense, net increased by approximately $236,000 to approximately $238,000 comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. The increase was primarily due to the approximately $231,000 change in fair value of derivative liabilities.

### Comparison of Nine Months Ended September 30, 2018 and 2017

The amounts presented in this comparison section are rounded to the nearest thousand.

### Revenue and Gross Profit

The following table presents the profitability of sales for the periods presented:

|  | Nine months ended September 30, 2018 | Nine months ended September 30, 2017 |
| --- | ---: | ---: |
| Product sales | $270,000 | $383,000 |
| Royalties | 288,000 | 141,000 |
| Total revenues | 558,000 | 524,000 |
| Product cost of sales | 132,000 | 812,000 |
| Total cost of sales | 132,000 | 812,000 |
| Gross profit (loss) | $426,000 | $(288,000) |
| Gross margin % | 76% | (55)% |

20

Revenues increased by $34,000 to $558,000 comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The increase was primarily attributable to (i) a $147,000 increase in royalties for the nine months ended September 30, 2018 as a result of and in connection with the Aldeflour royalty buyout described above under “*Recent Developments – Aldeflour Royalty Buyout.”* As a result of the Aldeflour royalty buyout, the Company will no longer be receiving related royalties. The effect of the third quarter 2018 accrual was partially offset by a $113,000 decrease in Aurix product sales. Aurix revenues declined primarily due to lower enrollment in the CED study protocols (and resulting fewer treatments) as the Company's limited resources have impacted viability perceptions. Management believes quarterly Aurix revenues will remain insufficient to cover operating expenses until such time as CED enrollment can be substantially increased and/or alternative non-CED Aurix revenues can be established. Please refer to “*Recent Developments – Status of CED Program”* above.

Overall gross profit increased $714,000 to $426,000 while overall gross margin increased to 76% from (55)%, comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The increase in gross profit primarily reflects (i) approximately $147,000 of increased royalty revenue (with no associated cost) in the nine months ended September 30, 2018 due to the Aldeflour royalty buyout described above; and (ii) the effect of non-cash amortization expense recorded in the nine months ended September 30, 2017 relating to (x) approximately $548,000 of intangible technology assets and (y) approximately $91,000 for a prepaid royalty. As all intangible assets were considered impaired as of December 31, 2017, no amortization expense was recognized in the nine months ended September 30, 2018.

### Operating Expenses

Total operating expenses decreased approximately $4,594,000 to approximately $2,089,000 comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The decrease was due to (i) the $2.1 million goodwill impairment charge recognized in the nine months ended September 30, 2017 and (ii) decreases across substantially all expense components from reduced headcount and numerous cost saving initiatives. A discussion of the various components of operating expenses follows below.

S*ales and Marketing*

Sales and marketing expenses decreased approximately $438,000 (82%) to $99,000 comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The decrease was primarily due to the elimination of the remaining direct sales personnel early in the first quarter 2018.

#### Research and Development

Research and development expenses decreased approximately $515,000 (51%) to approximately $494,000 comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The decrease was primarily due to (i) reduced headcount in the Clinical Affairs area and corresponding lower compensation expenses, (ii) no depreciation expense in the nine months ended September 30, 2018 as software costs are now fully depreciated, and (iii) decreased clinical affairs costs for reduced CED activity.

#### General and Administrative

General and administrative expenses decreased approximately $1,562,000 (51%) to approximately $1,496,000 comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The decrease was primarily due to (i) lower compensation expense due to reduced headcount, (ii) lower professional fees including legal expenses, (iii) decreased depreciation expenses, and (iv) an increase in bad debt recoveries in the nine months ended September 30, 2018

#### Impairment of Goodwill

As a result of events and circumstances in the three months ended June 30, 2017, including a sustained reduction in our stock price, we determined that it was more likely than not that our fair value was reduced below the carrying value of our net equity, requiring an impairment test as of June 30, 2017. We compared our carrying value to our fair value as reflected by our June 30, 2017 market capitalization and concluded that our carrying value exceeded our fair value by approximately $2.8 million. Consequently, we recognized a non-cash goodwill impairment charge of approximately $2.1 million to write-down goodwill to its estimated fair value of zero as of June 30, 2017.

#### Other Income (Expense)

Other expense, net increased by approximately $237,000 to approximately $248,000 comparing the nine months ended September 30, 2018 to the nine months ended September 30, 2017. The increase was primarily due to the approximately $231,000 change in fair value of derivative liabilities.

### Liquidity and Capital Resources

We are rapidly depleting our cash resources and our ability to continue to operate is in immediate jeopardy. Please refer to “*Recent Developments – Status of CED Program” above.*

For the nine months ended September 30, 2018, we incurred net losses from operations of approximately $1.9 million. At September 30, 2018, we had cash and cash equivalents of approximately $0.25 million, total current assets of approximately $0.6 million and total current liabilities of approximately $1.3 million. As of November 12, 2018, we had cash and cash equivalents of approximately $0.6 million.

We have a history of losses and are not currently profitable. As a result of the application of fresh-start accounting on the date we emerged from bankruptcy protection in May 2016, our retained earnings (deficit) was zero and our total stockholders’ equity was approximately $17.9 million on such date. As of September 30, 2018, our accumulated deficit was approximately $22.6 million and our stockholders' deficit was approximately $0.6 million.

During the quarter ended September 30, 2017, we withdrew our attempted registered offering and related refinancing of our Series A Preferred Stock, and exercised our rights under the May 5, 2016 backstop commitment in full. As a result, we issued an aggregate of 12,800,000 shares of common stock for gross proceeds of approximately $3.0 million, which more than doubled the number of our outstanding shares of common stock. In June 2018, we issued an additional 1,000,000 shares of common stock for gross proceeds of $0.5 million pursuant to a securities purchase agreement with Rohto. In September 2018, we issued two convertible notes for net proceeds of approximately $0.3 million, and related stock purchase warrants, which are convertible into and exercisable for common stock as further described above under “*Recent Developments – Issuance of Convertible Notes and Warrants”* (which description is incorporated herein by reference). The convertible notes impose onerous interest and penalty provisions on the Company. We also entered into a royalty buyout agreement with the licensee of the Aldeflour product for proceeds of approximately $0.2 million to be received in the fourth quarter of 2018. Finally, on October 24, 2018, we entered into an Agreement for Sale of Intellectual Property (the “IP Sale Agreement”) and a License and Service Agreement (the “Service Agreement” and collectively the “Agreements”) with Rohto, as further described above under “*Recent Developments - Sale of Intellectual Property and License and Service Agreement with Rohto,”* which description is incorporated herein by reference.

At September 30, 2018, we had cash and cash equivalents on hand of approximately $0.25 million and $0.35 million of convertible notes payable. The notes mature nine months from the date of issuance (June 17, 2019) and, in addition to any original issue discount, accrue interest at a rate of 12% per year. The Company may prepay the notes, in whole or in part, for 130% of outstanding principal and interest ending on the date that is 90 days following the date of issuance, and for 145% of outstanding principal and interest at any time commencing on the date that is 91 days following the date of issuance and ending on the date that is 180 days following the date of issuance, but only if the Company is not then in default under the notes. Beginning on the date that is 181 days following the date of issuance, the Company may no longer prepay the notes. The maturity date of the note issued to EMA may be extended up to one year beyond the original maturity date at the option of EMA.

Our continuing losses and depleted cash resources raise substantial doubt about our ability to continue as a going concern, and we need to raise substantial additional funds immediately in order to continue to conduct our business. If we are unable within the next 90 days to secure sufficient capital to fund our ongoing operating activities, we will likely be required to cease operations and liquidate our assets. If we were required to liquidate today, the holders of our common stock would not receive any consideration for their common stock as a result of the liquidation preference of the holder of our Series A Preferred Stock.

Even assuming we succeed in raising sufficient additional funds in the near future to avoid a cessation of business operations, we expect to incur losses and negative operating cash flows in the foreseeable future. We may never generate sufficient revenues to achieve and maintain profitability. Historically, we have financed our operations through a combination of the sale of debt, equity and equity-linked securities, licensing, royalty, and product revenues. We will no longer have the benefit of royalty revenues from the Aldeflour product as a result of the Aldeflour royalty buyout described above under “*Recent Developments – Aldeflour Royalty Buyout,”* which description is incorporated herein by reference. Until we can generate a sufficient amount of revenues to finance our cash requirements, which we may never do, we need to finance future cash needs. It is substantially uncertain whether we will be able to obtain such financing on satisfactory terms or at all.

Any equity financings may cause further substantial dilution to our stockholders and could involve the issuance of securities with rights senior to the common stock. Any allowed debt financings (which are severely restricted under the terms of the convertible notes and the Certificate of Designations for our Series A Preferred Stock) may require us to comply with additional onerous financial covenants and restrict our business operations. Our ability to complete additional financings is dependent on, among other things, market reception of the Company and perceived likelihood of success of our business model, the state of the capital markets at the time of any proposed equity or debt offering, state of the credit markets at the time of any proposed loan financing, and on the relevant transaction terms, among other things. We may not be able to obtain additional capital as required to finance our efforts, through equity or debt financings, other transactions, or any combination thereof, on satisfactory terms or at all. Additionally, any such financing, if at all obtained, may not be adequate to meet our capital needs and to support our operations.

Even assuming we succeed in raising substantial additional funds immediately to avoid liquidation, if we are unable to secure sufficient capital to fund our operating activities beyond the immediate future or we are unable to increase revenues significantly over that time period, we may be forced to further delay the completion of, or significantly reduce the scope of, our current business plan, delay the pursuit of commercial insurance reimbursement for our wound treatment technologies, and postpone the hiring of new personnel. If we are unable to secure sufficient capital to fund our operating activities and are unable to increase revenues significantly, we will likely be required to cease operations.

Our business is subject to certain risks and uncertainties including those described in "*Item 1.A Risk Factors"* in our Annual Report on Form 10-K for the year ended December 31, 2017.

### Cash Flows

Net cash provided by (used in) operating, investing, and financing activities for the periods presented were as follows (in millions):

|  | Nine months ended September 30, 2018 | Nine months ended September 30, 2017 |
| --- | ---: | ---: |
| Cash flows used in operating activities | $(1.3) | $(3.7) |
| Cash flows used in investing activities | $- | $- |
| Cash flow provided by financing activities | $0.8 | $3.0 |

#### Operating Activities

Cash used in operating activities for the nine months ended September 30, 2018 of approximately $1.3 million primarily reflects our net loss of approximately $1.9 million adjusted by (i) approximately $0.2 million change in fair value of derivative liabilities, (ii) approximately $0.1 million of depreciation expense, and (iii) an approximately $0.5 million increase for changes in operating assets and liabilities partially offset by an approximate $0.2 million bad debt recovery.

Cash used in operating activities for the nine months ended September 30, 2017 of approximately $3.7 million primarily reflects our net loss of approximately $7.0 million adjusted by (i) approximately $2.1 million for the impairment of goodwill, (ii) approximately $0.9 million of depreciation and amortization expense and (iii) an approximate $0.4 million increase for changes in operating assets and liabilities partially offset by an approximate $0.1 million bad debt recovery.

#### Investing Activities

We did not have any material investing activities for the nine months ended September 30, 2018 and 2017.

#### Financing Activities

Cash provided by financing activities for the nine months ended September 30, 2018 of $0.8 million represents the sale of 1,000,000 shares of common stock to Rohto for net proceeds of $0.5 million in June 2018 and net proceeds of approximately $0.3 million from the issuance of two convertible notes in September 2018.

Cash provided by financing activities for the nine months ended September 30, 2017 consisted of $3.0 million in gross proceeds from the call of the Backstop Commitment in full.

### Inflation

The Company believes that the rates of inflation in recent years have not had a significant impact on its operations.

### Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements.

### Critical Accounting Policies

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results of operations and that requires management’s most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect of matters that are inherently uncertain. We have identified the following accounting policies as critical to the successor company.

#### Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, contingent liabilities, fair value and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates.

#### Revenue Recognition

Prior to January 1, 2018, revenues were recognized when the four basic criteria for recognition were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured. The Company adopted new accounting guidance for revenue recognition effective January 1, 2018 which did not have a material impact on the Company’s financial statements. Beginning January 1, 2018, the Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.

We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not maintain a reserve for returned products as in the past those returns have not been material and are not expected to be material in the future.

Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees and are reflected as royalties in the condensed consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.

In July 2017, the FASB issued guidance intended to simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round features when assessing whether the instrument is indexed to its own stock for purposes of determining liability or equity classification. The Company adopted this guidance as of July 1, 2018.

We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our results of operations, financial position, or cash flows.

## Controls and procedures

As filed, 2,173 characters.

### Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management has carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of September 30, 2018. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Our recent reduction in staff may affect our ability to conduct our operations and other functions effectively, which may materially affect our internal control over financial reporting in future periods.

### PART II

### OTHER INFORMATION

Filed Nov 16, 2018.
Source: SEC EDGAR, the filing index for accession 0001437749-18-021015. Last ingested by Listed: Nov 14, 2026, 23:44 ET. No prices; not investment advice.
